Differences Between Right-Sided and Left-Sided Colon Cancer

Colorectal cancer is not a single disease but rather a heterogeneous malignancy whose biological behavior, clinical presentation, and therapeutic response vary significantly depending on tumor location within the colon. A clinically meaningful distinction exists between right-sided and left-sided colorectal cancers—defined anatomically by the splenic flexure, with right-sided tumors arising proximal to this landmark (cecum, ascending colon, hepatic flexure, and transverse colon) and left-sided tumors arising distal to it (splenic flexure, descending colon, sigmoid colon, and rectum).

Right-sided colorectal cancers are more frequently associated with microsatellite instability (MSI-H), CpG island methylator phenotype (CIMP), and BRAF V600E mutations. These molecular features correlate with distinct histopathological characteristics: tumors tend to be larger, exophytic, mucinous or poorly differentiated, and often present with iron-deficiency anemia due to chronic occult bleeding. Patients may remain asymptomatic until advanced stages, when symptoms such as fatigue, abdominal discomfort, or palpable mass emerge.

In contrast, left-sided colorectal cancers more commonly harbor chromosomal instability (CIN), KRAS and NRAS mutations, and TP53 alterations. Histologically, they are typically stenosing, ulcerated, and moderately differentiated adenocarcinomas. Clinical presentation is often earlier and more overt—patients frequently report hematochezia, change in bowel habits (e.g., constipation or narrowing of stool), or obstructive symptoms such as colicky abdominal pain and distension.

Emerging evidence underscores that tumor sidedness independently influences prognosis and treatment efficacy. Multiple randomized trials—including CALGB/SWOG 80405 and FIRE-3—demonstrated that patients with left-sided metastatic colorectal cancer derive greater overall survival benefit from anti-EGFR monoclonal antibodies (cetuximab, panitumumab) when used in combination with chemotherapy, particularly in RAS wild-type disease. Conversely, right-sided tumors show markedly diminished response to EGFR inhibition and may derive relatively greater benefit from bevacizumab-based regimens.

This biologic and clinical divergence has prompted oncology guidelines—including those from the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO)—to incorporate tumor location as a key factor in treatment decision-making for metastatic disease. Ongoing research continues to explore whether sidedness reflects underlying embryologic, vascular, microbiomic, or immune microenvironment differences that could inform future biomarker-driven strategies.